Gensight Biologics will participate to the 4th Annual Gene Therapy for Rare Disorders Europe to be held in a virtual format from Monday 26 October to Wednesday 28 October 2020.
Magali Taiel, Chief Medical Officer, will give an oral presentation and will be part of a panel discussion.
Oral Presentation – Title: Outlining Key Regulatory Pathway Differences in the US & Europe – Learnings from development of Lumevoq Gene Therapy in LHON subjects
- Comparing and contrasting EMA & FDA regulatory pathways
- Working effectively with regulators to meet their requirements
- Outlining the advantages of more common guidances between different regulatory agencies
Date: Tuesday, 27 October, 2020
Time: 11:30am – 12:00pm GMT
Session: CLINICAL – Exploring the European Regulatory Landscape
Panel Discussion – Title: Exploring the Industry Response to COVID-19 & Identifying Key Learnings
Date: Tuesday, 27 October, 2020
Time: 4:45am – 5:15pm GMT
Session: SHARING UPDATES ON THE FUTURE GENE THERAPY LANDSCAPE